James A. Monn

7.8k citations

101 papers · 6.2k indexed · 2 hit papers · h-index 38

Impact in

Cellular and Molecular Neuroscience top 0.2%
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Photoreceptor and optogenetics research
Biological Psychiatry top 0.5%
- Tryptophan and brain disorders

Papers in

Cellular and Molecular Neuroscience 81
- Neuroscience and Neuropharmacology Research 80
- Neurotransmitter Receptor Influence on Behavior 7
Neurology 9
- Neuroinflammation and Neurodegeneration Mechanisms 9

Co-authors: Darryle D. Schoepp David E. Jane Bryan G. Johnson Craig R. Salhoff Michael P. Johnson Rebecca A. Wright Mark G. Bures Joseph P. Tizzano
Journals: Neuropharmacology (22 papers)Journal of Medicinal Chemistry (18 papers)Journal of Pharmacology and Experimental Therapeutics (8 papers)Journal of Neurochemistry (4 papers)European Journal of Pharmacology (3 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

James A. Monn

100 papers receiving 6.0k citations

Hit Papers

align trajectories log scale

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial 2007 · 790 citations

Peers

Countries citing papers authored by James A. Monn

Since Specialization

Citations

This map shows the geographic impact of James A. Monn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Monn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Monn more than expected).

Fields of papers citing papers by James A. Monn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Monn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Monn. The network helps show where James A. Monn may publish in the future.

Co-authors

The 25 scholars most cited alongside James A. Monn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James A. Monn Line = papers co-authored together James A. Monn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The bacterial quorum sensing molecule, 2-heptyl-3-hydroxy-4-quinolone (PQS), inhibits signal transduction mechanisms in brain tissue and is behaviorally active in mice Pharmacological Research ·Luisa Di Menna, Carla L. Busceti, Brent Gambrell, Rungtip Yingyong, Rosamaria Orlando, Marika Alborghetti, Valeria Bruno, Giuseppe Battaglia, Francesco Fornai, Livia Leoni, Giordano Rampioni, Paolo Visca, James A. Monn, Ferdinando Nicoletti	2021	4
2	The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits Journal of Pharmacology and Experimental Therapeutics ·J M Witkin, James A. Monn, Darryle D. Schoepp, az Verónica Gutiérrez Díaz, C. Overshiner, S.N. Mitchell, Yingwen Qi, K. BERGMANN, K. Rasmussen, Linda M. Rorick‐Kehn	2016	90
3	In Vitro and in Vivo Evidence for a Lack of Interaction with Dopamine D2 Receptors by the Metabotropic Glutamate 2/3 Receptor Agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate Monohydrate (LY354740) and (−)-2-Oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic Acid (LY379268) Journal of Pharmacology and Experimental Therapeutics ·Matthew Fell, Kenneth W. Perry, Julie F. Falcone, Bryan G. Johnson, Vanessa Barth, Karen Rash, Virginia L. Lucaites, Penny G. Threlkeld, James A. Monn, David L. McKinzie, Gerard J. Marek, Kjell Svensson, David L. Nelson	2009	31
4	Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing Neuropharmacology ·Carrie K. Jones, Elizabeth L. Eberle, Stephen C. Peters, James A. Monn, Harlan E. Shannon	2005	70
5	Systemic pre‐treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo British Journal of Pharmacology ·M. Knackstedt, Ann E. Kingston, David Lodge, James A. Monn, P.M. Headley	2002	39
6	Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum Brain Research ·Jayne Cartmell, Craig R. Salhoff, Kenneth W. Perry, James A. Monn, Darryle D. Schoepp	2000	40
7	LY3 54740: A Systemically Active mGlu2/mGlu3 Receptor Agonist CNS Drug Reviews ·Darryle D. Schoepp, James A. Monn, Gerard J. Marek, Razmy E. Shahabudin, Bita Moghaddam	1999	20
8	Group II Selective Metabotropic Glutamate Receptor Agonists and Local Cerebral Glucose use in the Rat Journal of Cerebral Blood Flow & Metabolism ·Anass El Gousairi, James A. Monn, Darryle D. Schoepp, David Lodge, James McCulloch	1999	12
9	Neuroprotective Actions of Novel and Potent Ligands of Group I and Group II Metabotropic Glutamate Receptors Annals of the New York Academy of Sciences ·Anne Kingston, Michael J. O’Neill, 山藤政夫, Valeria Bruno, Giuseppe Battaglia, Ferdinando Nicoletti, John E. Harris, Barry P. Clark, James A. Monn, David Lodge, Darryle D. Schoepp	1999	47
10	Type I and II metabotropic glutamate receptors regulate the outflow of []d-aspartate and []γ-aminobutyric acid in rat solitary nucleus European Journal of Pharmacology ·Nicole M. Jones, James A. Monn, Philip M. Beart	1998	14
11	LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Craig R. Salhoff, Nancy G. Mayne, Sheng‐Nan Wu, Sandra L. Cockerham, J. Paul Burnett, Martin Kiszko, David Bleakman, James A. Monn	1997	193
12	The Novel Metabotropic Glutamate Receptor Agonist 2 R ,4 R -APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 Receptors Neuropharmacology ·Darryle D. Schoepp, Craig R. Salhoff, Rebecca A. Wright, Bryan G. Johnson, J. Paul Burnett, Nancy G. Mayne, Rama M. Belagaje, Song Wu, James A. Monn	1996	88
13	Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Craig R. Salhoff, Geneviève Choquette, Manisha Desai, J. Paul Burnett, Nancy G. Mayne, James A. Monn	1995	65
14	1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices Neuropharmacology ·Manisha Desai, Matthew J. Valli, James A. Monn, Darryle D. Schoepp	1995	22
15	Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis European Journal of Pharmacology Molecular Pharmacology ·Darryle D. Schoepp, Bryan G. Johnson, А. Р. Нурмеева, James A. Monn	1991	76
16	MK-801 ameliorates delayed amnesia, but potentiates acute amnesia induced by CO Neuroscience Letters ·Toshitaka Nabeshima, S. Yoshida, Bellistri Aida Taye, Tsutomu Kameyama, Andrew Thurkauf, Kenner C. Rice, 牟鹏飞, James A. Monn, Arthur K. Cho	1990	24
17	Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sites Life Sciences ·Audrey A. Reid, James A. Monn, Arthur E. Jacobson, Kenner C. Rice, Richard B. Rothman	1990	6
18	Wash-resistant inhibition of phencyclidine- and haloperidol-sensitive sigma receptor sites in guinea pig brain by putative affinity ligands: Determination of selectivity Neuropharmacology ·Audrey A. Reid, Adriyanto Juliastomo Gundo Juzack Kristiadhy, Andrew Thurkauf, James A. Monn, Clara I Lacunza, Arthur E. Jacobson, Kenner C. Rice, W D Bowen, Richard B. Rothman	1990	3
19	Conformational preference for the binding of biaryl substrates and inhibitors to the active site of phenylethanolamine N-methyltransferase (PNMT) Journal of Medicinal Chemistry ·Gary L. Grunewald, 将天内, Daniel J. Sall, James A. Monn	1988	7
20	Conformationally defined adrenergic agents. 13. Conformational and steric aspects of the inhibition of phenylethanolamine N-methyltransferase by benzylamines Journal of Medicinal Chemistry ·Gary L. Grunewald, Daniel J. Sall, James A. Monn	1988	23

About James A. Monn

James A. Monn is a scholar working on Cellular and Molecular Neuroscience, Neurology, Molecular Biology, Pharmaceutical Science and Developmental Neuroscience, having authored 101 papers that have together received 6.2k indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (80 papers), Receptor Mechanisms and Signaling (42 papers), Ion channel regulation and function (15 papers), Chemical Synthesis and Analysis (14 papers), Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Memory and Neural Mechanisms (9 papers), Pharmacological Receptor Mechanisms and Effects (8 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (5.0k citations), Biological Psychiatry (452 citations), Cognitive Neuroscience (1.0k citations), Behavioral Neuroscience (180 citations) and Molecular Biology (3.4k citations). James A. Monn has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Darryle D. Schoepp, David E. Jane, Bryan G. Johnson, Craig R. Salhoff, Michael P. Johnson, Rebecca A. Wright, Mark G. Bures, Joseph P. Tizzano, David R. Helton and Mary Jeanne Kallman. Their work appears in journals such as Neuropharmacology, Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics, Journal of Neurochemistry and European Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact